Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory CD20-positive B-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hairy Cell Leukemia
• Indolent B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• CC-486 (azacitidine)
• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Joseph Tuscano | Conditions: Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED